Iara Aimê Cardoso

Ms. Iara Aimê Cardoso

School of Biochemistry and Biomedical Sciences, University of Bristol, Bristol, City of Bristol, UK
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
STSusana Vázquez Torres
Susana Vázquez Torres
MBMelisa Benard-Valle
Melisa Benard-Valle
Stephen MackessyStephen Mackessy
Stephen Mackessy
SMStefanie Menzies
Stefanie Menzies
NCNicholas Casewell
Nicholas Casewell
DBDavid Baker
David Baker
Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more1,2. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage3 and inhibition of nicotinic acetylcholine receptors, resulting in life-threatening neurotoxicity4. At present, the only available treatments for snakebites consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs5,6,7. Here we used deep learning methods to de novo design proteins to bind short-chain and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtained protein designs with remarkable thermal stability, high binding affinity and near-atomic-level agreement with the computational models. The designed proteins effectively neutralized all three 3FTx subfamilies in vitro and protected mice from a lethal neurotoxin challenge. Such potent, stable and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our results highlight how computational design could help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for the development of therapies for neglected tropical diseases.

10 March 2023 in Science
Verified
Journal Article
Closed access
KHKevin G. Hicks
Kevin G. Hicks
ACAhmad A. Cluntun
Ahmad A. Cluntun
HSHeidi L. Schubert
Heidi L. Schubert
SHSean R. Hackett
Sean R. Hackett
JBJordan A. Berg
Jordan A. Berg
JRJared Rutter
Jared Rutter
Metabolic networks are interconnected and influence diverse cellular processes. The protein-metabolite interactions that mediate these networks are frequently low affinity and challenging to systematically discover. We developed mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically (MIDAS) to identify such interactions. Analysis of 33 enzymes from human carbohydrate metabolism identified 830 protein-metabolite interactions, including known regulators, substrates, and products as well as previously unreported interactions. We functionally validated a subset of interactions, including the isoform-specific inhibition of lactate dehydrogenase by long-chain acyl–coenzyme A. Cell treatment with fatty acids caused a loss of pyruvate-lactate interconversion dependent on lactate dehydrogenase isoform expression. These protein-metabolite interactions may contribute to the dynamic, tissue-specific metabolic flexibility that enables growth and survival in an ever-changing nutrient environment.

1 April 2017 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
JBJohara Boldrini-França
Johara Boldrini-França
CCCamila Takeno Cologna
Camila Takeno Cologna
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
Karla De Castro Figueiredo BordonKarla De Castro Figueiredo Bordon
Karla De Castro Figueiredo Bordon
FAFernanda Gobbi Amorim
Fernanda Gobbi Amorim
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes

1 January 2019 in Journal of Proteomics
Verified
Journal Article
Closed access
IOIsadora Sousa de Oliveira
Isadora Sousa de Oliveira
ICIara Aimê Cardoso
Iara Aimê Cardoso
Karla De Castro Figueiredo BordonKarla De Castro Figueiredo Bordon
Karla De Castro Figueiredo Bordon
SCSante Emmanuel Imai Carone
Sante Emmanuel Imai Carone
JBJohara Boldrini-França
Johara Boldrini-França
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes

29 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
SAShirin Ahmadi
Shirin Ahmadi
NBNick J. Burlet
Nick J. Burlet
MBMelisa Benard-Valle
Melisa Benard-Valle
AGAlid Guadarrama-Martínez
Alid Guadarrama-Martínez
SKSamuel Kerwin
Samuel Kerwin
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option 1 . Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species 2 . There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms 3 . Here we addressed this challenge by immunizing an alpaca and a llama with the venoms of 18 different snakes, including mambas, cobras and a rinkhals, constructing phage display libraries, and identifying high-affinity broadly neutralizing nanobodies. We combined eight of these nanobodies into a defined oligoclonal mixture, resulting in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin families or subfamilies. This antivenom effectively prevented venom-induced lethality in vivo across 17 African elapid snake species and markedly reduced venom-induced dermonecrosis for all tested cytotoxic venoms. The recombinant antivenom performed better than a currently used plasma-derived antivenom and therefore shows considerable promise for comprehensive, continent-wide protection against snakebites by all medically relevant African elapids.

1 November 2014 in Toxicon
Verified
Journal Article
Closed access
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
FAFernanda Gobbi Amorim
Fernanda Gobbi Amorim
FCFelipe Augusto Cerni
Felipe Augusto Cerni
Karla De Castro Figueiredo BordonKarla De Castro Figueiredo Bordon
Karla De Castro Figueiredo Bordon
ICIara Aimê Cardoso
Iara Aimê Cardoso
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes